Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Uncertainties: Overall Survival and Second Primaries
John discusses the need to watch overall survival, possible effects on second primary cancers, and post-recurrence treatments.
Play episode from 04:18
Transcript
